<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109339</url>
  </required_header>
  <id_info>
    <org_study_id>20190501</org_study_id>
    <nct_id>NCT04109339</nct_id>
  </id_info>
  <brief_title>Effects of Oxytocin on Hemodynamics in Patients Undergoing Laparoscopic Myomectomy</brief_title>
  <official_title>Effects of Oxytocin on Hemodynamics in Patients Undergoing Laparoscopic Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will study the effect of oxytocin on hemodynamics in patients undergoing
      laparoscopic myomectomy, and how to prevent and manage such hemodynamic changes
      effectively.It provides a reference for the rational use of oxytocin in clinical practice,
      which can not only effectively contract the uterus and reduce bleeding, but also reduce the
      influence on hemodynamics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of traditional hemodynamic parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>Parameters including SBP, DBP, MAP (mmHg) were measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of traditional hemodynamic parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>HR (beats/min) was measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of volume management parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>SVV (%) was measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of volume management parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>SVRI (dynes-sec/cm-5) was measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of volume management parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>CI (l/min/m2) was measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of volume management parameters after oxytocin use during laparoscopic hysteromyomectomia.</measure>
    <time_frame>&quot;before induction&quot;, &quot;before incision&quot;, &quot;before oxytocin intramuscular injection&quot;, and &quot;20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec,180 sec after oxytocin intramuscular injection&quot;.</time_frame>
    <description>CO (l/min) was measured by a Mostcare hemodynamic monitor.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Oxytocin</condition>
  <condition>Hemodynamic Monitoring</condition>
  <condition>Laparoscopic Surgery</condition>
  <arm_group>
    <arm_group_label>group 1 with no oxytocin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 with oxytocin 10 U IM + oxytocin 10 U IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 with oxytocin 20 U IM + oxytocin 0 U IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4 with oxytocin 0 U IM + oxytocin 20 U IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.</description>
    <arm_group_label>group 2 with oxytocin 10 U IM + oxytocin 10 U IV</arm_group_label>
    <arm_group_label>group 3 with oxytocin 20 U IM + oxytocin 0 U IV</arm_group_label>
    <arm_group_label>group 4 with oxytocin 0 U IM + oxytocin 20 U IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General anesthesia for gynecological laparoscopic surgery,ASA I~III

        Exclusion Criteria:

          -  Oxytocin use contraindications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhuan Zhang</last_name>
    <phone>+8615062791355</phone>
    <phone_ext>+8615062791355</phone_ext>
    <email>zhangzhuanjy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuan Zhang</last_name>
      <phone>+8615062791355</phone>
      <phone_ext>+8615062791355</phone_ext>
      <email>zhangzhuanjy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>Hemodynamic</keyword>
  <keyword>Myomectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

